BACKGROUND: The emergence of bla(KPC)-containing Klebsiella pneumoniae (KPC-Kp) isolates is attracting significant attention. Outbreaks in the Eastern USA have created serious treatment and infection control problems. A comparative multi-institutional analysis of these strains has not yet been performed. METHODS: We analysed 42 KPC-Kp recovered during 2006-07 from five institutions located in the Eastern USA. Antimicrobial susceptibility tests, analytical isoelectric focusing (aIEF), PCR and sequencing of bla genes, PFGE and rep-PCR were performed. Results By in vitro testing, KPC-Kp isolates were highly resistant to all non-carbapenem beta-lactams (MIC(90)s >or= 128 mg/L). Among carbapenems, MIC(50/90)s were 4/64 mg/L for imipenem and meropenem, 4/32 mg/L for doripenem and 8/128 for ertapenem. Combinations of clavulanate or tazobactam with a carbapenem or cefepime did not significantly lower the MIC values. Genetic analysis revealed that the isolates possessed the following bla genes: bla(KPC-2) (59.5%), bla(KPC-3) (40.5%), bla(TEM-1) (90.5%), bla(SHV-11) (95.2%) and bla(SHV-12) (50.0%). aIEF of crude beta-lactamase extracts from these strains supported our findings, showing beta-lactamases at pIs of 5.4, 7.6 and 8.2. The mean number of beta-lactamases was 3.5 (range 3-5). PFGE demonstrated that 32 (76.2%) isolates were clonally related (type A). Type A KPC-Kp isolates (20 bla(KPC-2) and 12 bla(KPC-3)) were detected in each of the five institutions. rep-PCR showed patterns consistent with PFGE. CONCLUSIONS: We demonstrated the complex beta-lactamase background of KPC-Kp isolates that are emerging in multiple centres in the Eastern USA. The prevalence of a single dominant clone suggests that interstate transmission has occurred.
BACKGROUND: The emergence of bla(KPC)-containing Klebsiella pneumoniae (KPC-Kp) isolates is attracting significant attention. Outbreaks in the Eastern USA have created serious treatment and infection control problems. A comparative multi-institutional analysis of these strains has not yet been performed. METHODS: We analysed 42 KPC-Kp recovered during 2006-07 from five institutions located in the Eastern USA. Antimicrobial susceptibility tests, analytical isoelectric focusing (aIEF), PCR and sequencing of bla genes, PFGE and rep-PCR were performed. Results By in vitro testing, KPC-Kp isolates were highly resistant to all non-carbapenem beta-lactams (MIC(90)s >or= 128 mg/L). Among carbapenems, MIC(50/90)s were 4/64 mg/L for imipenem and meropenem, 4/32 mg/L for doripenem and 8/128 for ertapenem. Combinations of clavulanate or tazobactam with a carbapenem or cefepime did not significantly lower the MIC values. Genetic analysis revealed that the isolates possessed the following bla genes: bla(KPC-2) (59.5%), bla(KPC-3) (40.5%), bla(TEM-1) (90.5%), bla(SHV-11) (95.2%) and bla(SHV-12) (50.0%). aIEF of crude beta-lactamase extracts from these strains supported our findings, showing beta-lactamases at pIs of 5.4, 7.6 and 8.2. The mean number of beta-lactamases was 3.5 (range 3-5). PFGE demonstrated that 32 (76.2%) isolates were clonally related (type A). Type A KPC-Kp isolates (20 bla(KPC-2) and 12 bla(KPC-3)) were detected in each of the five institutions. rep-PCR showed patterns consistent with PFGE. CONCLUSIONS: We demonstrated the complex beta-lactamase background of KPC-Kp isolates that are emerging in multiple centres in the Eastern USA. The prevalence of a single dominant clone suggests that interstate transmission has occurred.
Authors: H Yigit; A M Queenan; G J Anderson; A Domenech-Sanchez; J W Biddle; C D Steward; S Alberti; K Bush; F C Tenover Journal: Antimicrob Agents Chemother Date: 2001-04 Impact factor: 5.191
Authors: Ellen Smith Moland; Nancy D Hanson; Vicki L Herrera; Jennifer A Black; Thomas J Lockhart; Ashfaque Hossain; Judith A Johnson; Richard V Goering; Kenneth S Thomson Journal: J Antimicrob Chemother Date: 2003-03 Impact factor: 5.790
Authors: David L Paterson; Kristine M Hujer; Andrea M Hujer; Bethany Yeiser; Michael D Bonomo; Louis B Rice; Robert A Bonomo Journal: Antimicrob Agents Chemother Date: 2003-11 Impact factor: 5.191
Authors: Patricia A Bradford; Simona Bratu; Carl Urban; Melissa Visalli; Noriel Mariano; David Landman; James J Rahal; Steven Brooks; Sanda Cebular; John Quale Journal: Clin Infect Dis Date: 2004-06-14 Impact factor: 9.079
Authors: Hesna Yigit; Anne Marie Queenan; J Kamile Rasheed; James W Biddle; Antonio Domenech-Sanchez; Sebastian Alberti; Karen Bush; Fred C Tenover Journal: Antimicrob Agents Chemother Date: 2003-12 Impact factor: 5.191
Authors: Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Rangarajan Sampath; David J Ecker; Robert A Bonomo Journal: J Antimicrob Chemother Date: 2010-06-10 Impact factor: 5.790
Authors: Andrea Endimiani; Andrea M Hujer; Kristine M Hujer; Julian A Gatta; Andrew C Schriver; Michael R Jacobs; Louis B Rice; Robert A Bonomo Journal: J Clin Microbiol Date: 2010-05-26 Impact factor: 5.948
Authors: Roberto Viau; Karen M Frank; Michael R Jacobs; Brigid Wilson; Keith Kaye; Curtis J Donskey; Federico Perez; Andrea Endimiani; Robert A Bonomo Journal: Clin Microbiol Rev Date: 2016-01 Impact factor: 26.132
Authors: Harald Peter; Kathrine Berggrav; Peter Thomas; Yvonne Pfeifer; Wolfgang Witte; Kate Templeton; Till T Bachmann Journal: J Clin Microbiol Date: 2012-10-03 Impact factor: 5.948
Authors: Krisztina M Papp-Wallace; Christopher R Bethel; Anne M Distler; Courtney Kasuboski; Magdalena Taracila; Robert A Bonomo Journal: Antimicrob Agents Chemother Date: 2009-12-14 Impact factor: 5.191
Authors: Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Eliana S Armstrong; Yuvraj Choudhary; James B Aggen; Robert A Bonomo Journal: Antimicrob Agents Chemother Date: 2009-10 Impact factor: 5.191
Authors: Latania K Logan; Rachel L Medernach; Jared R Rispens; Steven H Marshall; Andrea M Hujer; T Nicholas Domitrovic; Susan D Rudin; Xiaotian Zheng; Nadia K Qureshi; Sreenivas Konda; Mary K Hayden; Robert A Weinstein; Robert A Bonomo Journal: Pediatr Infect Dis J Date: 2019-06 Impact factor: 2.129